DNA X files 12b-25 delaying Q1 2026 10-Q
DNA X, Inc. notified the SEC that it could not timely file its Form 10-Q for the three months ended March 31, 2026.
Rhea-AI Filing Summary
DNA X, Inc. notified the SEC that it could not timely file its Form 10-Q for the three months ended March 31, 2026. The delay stems from the disposition of the company’s Legacy Business and the required discontinued operations accounting under ASC 205-20, which requires separating current results, retrospectively recasting prior periods, and computing the gain or loss on disposition and related income-tax allocation.
The company says the accounting complexity and the need for accurate retrospective adjustments have extended the financial close. DNA X expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date and anticipates reporting $3.6 million net loss from continuing operations for the three months ended March 31, 2026, compared to $0.7 million net loss for the three months ended March 31, 2025.
Positive
- None.
Negative
- None.
Insights
Discontinued-operations accounting is the core driver of the delay.
The filing cites ASC 205-20 and the need to present the Legacy Business as a discontinued operation, which requires separation of current-period results and retrospective recasting of prior-period comparatives. That work often demands additional tax allocation, working-capital adjustments, and footnote disclosures.
Completion depends on finalizing the disposition gain/loss and associated tax calculations; subsequent filings should show the separate discontinued-operation line items, the gain/loss on disposition, and updated prior-period comparatives.
Sale of the Legacy Business materially changed reported operations for Q1 2026.
The company attributes higher 2026 G&A to severance, bonuses, and professional fees tied to the sale, and signals an expected $3.6 million net loss from continuing operations for Q1 2026 versus $0.7 million in Q1 2025. These items will appear in the continuing-operations results and in sale-related disclosure.
Watch the filed Form 10-Q for the disclosed gain/loss on disposal, the income-tax allocation between continuing and discontinued operations, and the quantitative effect of severance and professional-fee charges.
Key Figures
Key Terms
ASC 205-20 regulatory
discontinued operations financial
retrospective recasting financial
FAQ
Why did DNA X (SONM) file a Form 12b-25 delaying its Q1 2026 10-Q?
When does DNA X expect to file the delayed Form 10-Q for Q1 2026?
What net loss does DNA X expect to report for continuing operations in Q1 2026?
What caused the increase in net loss for Q1 2026 at DNA X?
AI-generated analysis. How Rhea-AI works. Not financial advice.